MP07-66

SKU: orb1297904

Description

MP07-66 is a non-immunosuppressive FTY720 analog that induces apoptosis in chronic lymphocytic leukemia (CLL) cells by reactivating protein phosphatase 2A (PP2A). This mechanism supports its investigation in preclinical oncology research for both in vitro and in vivo models of B-cell malignancies.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1938056-90-6
• MW: 323.47
• Purity: 97.83% (May vary between batches)
• Formula: C₁₉H₃₃NO₃
• SMILES: CCCCCCOc1ccc(CNCC(OCC)OCC)cc1
• Target: Phosphatase
• Solubility: DMSO:250 mg/mL (772.87 mM)

Bioactivity

• In Vitro:
  CLL cells were incubated with increasing concentrations of MP07-66 (0-16 μM) for 24 and 48 hours and then subject to annexin V–PI flow cytometry. The level of apoptosis reached 50% and 80%, at 24 hours and 48 hours, respectively, at a MP07-66 concentration as high as 16 μM, which paralleled PARP cleavage, a marker of caspase-dependent apoptosis. In addition, the phosphorylation status of PP2A targets, namely Akt, GSK-3, and SHP-1, was negatively affected by the treatment with MP07-66, triggering known downstream events promoting apoptosis, such as Mcl-1 degradation and caspase-3 activation.

Storage & Handling

• Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

chronic lymphocytic leukemia, antitumor effects, Inhibitor, FTY720 analogue, immunosuppressive effects, MP07 66, MP0766, MP-07-66, MP07-66, inhibit, SET-PP2A, SET-PP2A complex, Phosphatase

Compound Identifiers

PubChem CID

154113489